Although there were no studies to discuss the roles of SCG5 in cancer, its family members secretogranin II and III have been seen to be overexpressed in prostate cancer (Courel et al., 2014) and small cell lung carcinoma (Togayachi et al., 2017), suggesting SCG5 may also be oncogenic for LSCC. Here, SCG5 is linked to prostate cancer.